San Diego, CA
Cardinal Health announced it has completed the spinoff of CareFusion Corp. through a pro rata distribution of approximately 81 percent of the shares of CareFusion common stock, launching it as an independent, publicly traded company.
“Our experienced management team and more than 15,000 employees begin ready to serve our global customers as a new public company,” said David L. Schlotterbeck, the named Chairman.
CareFusion opens regular-way trading on the New York Stock Exchange and will be included in the S&P 500 index. The new medical technology company is a leading provider of clinically proven products and services that help health care institutions worldwide measurably improve patient care.
Among other items, the CareFusion board of directors acted yesterday to name Schlotterbeck, 62, as chairman in addition to his existing CEO role, and Michael Losh, 63, as presiding director.
Cardinal Health distributed to its shareholders 0.5 shares of CareFusion common stock for each outstanding Cardinal Health common share held as of market close on Aug. 25. In addition, Cardinal Health retained approximately 41 million shares, which pursuant to the IRS private letter ruling for the spinoff, it is required to divest within five years. Including shares held by Cardinal Health, there are approximately 222 million shares of CareFusion common stock outstanding following the spinoff.
See the company press release.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.